Dr. Fizazi on pivotal TALAPRO-2 trial of talazoparib/enzalutamide in HRR gene–mutated mCRPC
Karim Fizazi, MD, PhD, highlights the TALAPRO-2 trial, which led to the FDA approval of talazoparib plus enzalutamide for patients with HRR gene–mutated metastatic castration-resistant prostate cancer.
Dr. Hutson on the future of the advanced renal cell carcinoma treatment paradigm
“The field of advanced RCC is evolving very quickly to a precision medicine approach where we're trying to individualize therapies,” says Thomas E. Hutson, DO, PharmD, FACP.
Dr. Hutson on how he treats advanced RCC patients who progress on first-line lenvatinib/pembrolizumab
“The goal at the end of the day is to get exposure of your patient [with renal cell carcinoma] to as many of the most active agents as possible,” says Thomas E. Hutson, DO, PharmD, FACP.
Pembrolizumab plus lenvatinib shows promise in nccRCC
Treatment with the first-line combination of pembrolizumab and lenvatinib led to durable anti-tumor activity in patients with non–clear cell renal cell carcinoma.
Dr. Loeb on the effect of a plant-based diet on functional outcomes in prostate cancer
"We found that consuming more plant-based food was associated with significantly better scores for the urinary domains of the quality of life questionnaire," says Stacy Loeb, MD, MSc.
Dr. Psutka on current and emerging uses for acupuncture in urology
“There are a lot of different ways that we can potentially use these complementary and alternative therapies to help mitigate symptoms in our patients across the realm of urology,” said Sarah P. Psutka, MD.
Dr. Morgans on real-world study comparing darolutamide, enzalutamide, and apalutamide in nmCRPC
"We found in both unadjusted and adjusted analyses that patients seemed to discontinue enzalutamide and apalutamide at slightly earlier time points than darolutamide," said Alicia Morgans, MD.
Dr. Gupta on 4-year data for enfortumab vedotin/pembrolizumab in urothelial carcinoma
Shilpa Gupta, MD, discusses long-term outcomes of the EV-103 trial, which explored the first-line combination of enfortumab vedotin and pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Dr. Siefker-Radtke on upfront erdafitinib/cetrelimab in cisplatin-ineligible urothelial cancer
“Our ultimate goal is to come up with strategies that really enhance the life expectancy and the treatment options for our patients with urothelial cancer,” says Arlene O. Siefker-Radtke, MD.
Combination therapy shows promising survival benefit in Black men with mCRPC
“This research shows the importance of diversity in clinical trials," said lead author Daniel J. George, MD.
Pembrolizumab/axitinib efficacy in ccRCC sustained at 5-year follow-up
At a median follow-up of 67.2 months, the combination of pembrolizumab and axitinib continued to show an overall survival and progression-free survival benefit over sunitinib monotherapy in the first-line setting.
Dr. Rini discusses the KEYNOTE-426 trial in advanced RCC
"In this trial, and in all the major IO/TKI trials, the checkpoint inhibitor stopped at 2 years. In this trial it was about 25% of patients who made it to that time point," says Brian I. Rini, MD.
Dr. McGregor discusses cabozantinib/nivolumab/ipilimumab in advanced RCC with variant histologies
"Unfortunately, I don't think that the triplet of cabo/nivo/ipi is ready as the current dosing for use in RCC with variant histology," says Bradley McGregor, MD.
Extended lymphadenectomy provides no benefit over standard lymphadenectomy in MIBC
“Both the SWOG S1011 and the LEA trial show very clearly that a bilateral standard node dissection confined to the true pelvis is the standard of care for patients with curable muscle-invasive bladder cancer," says Seth P. Lerner, MD, FACS.
Cabozantinib/atezolizumab does not improve PFS or OS in advanced RCC
“The addition of atezolizumab to cabozantinib did not result in improved clinical outcomes in patients with mRCC who progressed on or after prior ICI treatment,” said Toni K. Choueiri, MD.
Erdafitinib extends survival in post-immunotherapy, FGFR-altered urothelial cancer
In this patient population, erdafitinib reduced the risk of death by 36% versus physician's choice of chemotherapy.
Enfortumab vedotin/pembrolizumab combo shows safety, efficacy in metastatic urothelial carcinoma
"In EV-103 dose escalation/cohort A, the safety profile of the combination was manageable, with no new safety concerns observed at nearly 4 years of follow-up," said Shilpa Gupta, MD.
Lenvatinib/pembrolizumab efficacy in renal cell carcinoma sustained at 4-year follow-up
At a median follow-up of about 50 months, lenvatinib plus pembrolizumab maintained an overall survival benefit compared with sunitinib in patients with advanced renal cell carcinoma.
Dr. Psutka on the use of acupuncture prior to BCG therapy in patients with NMIBC
"All the patients said that they were pleased with the acupuncture that they received, and about 75% said that they would refer other people going through BCG to acupuncture," says Sarah P. Psutka, MD, MS.
Dr. Garje compares outcomes in sacromatoid versus classic urothelial carcinoma
"There was a striking decreased survival for patients who had sarcomatoid histology compared to the ones who had the classic variant urothelial histology," says Rohan Garje, MD.
Trastuzumab deruxtecan shows antitumor activity in HER2+ tumors, including bladder cancer
The antibody-drug conjugate trastuzumab deruxtecan is being explored across a wide-range of HER2-positive solid tumors, including difficult-to-treat cancers.
Talazoparib plus enzalutamide significantly delays progression in HRR gene–altered mCRPC
The benefit in radiographic progression-free survival extended across all subgroups of patients with HRR-deficient metastatic castration-resistant prostate cancer.
Worse rPFS, OS observed in patients with BRCA-mutated mCRPC vs non-BRCA
“These results further support the importance of screening for germline and somatic BRCA1/2 alterations to deliver more precise care for our patient," says David Olmos, MD, PhD.
Dr. Olmos on outcomes in first-line mCRPC based on BRCA/HRR status
David Olmos, MBBS, MSc, PhD, discusses research presented at the ASCO 2023 Annual Meeting assessing outcomes with first-line novel hormonal therapy or taxane therapy in metastatic castration-resistant prostate cancer based on patients' BRCA/HRR status.
Dr. Hutson presents follow-up CLEAR study data on lenvatinib/pembrolizumab in aRCC
"The overall survival, Kaplan Meier curves, are maintained with a hazard ratio of 0.79 for the intent-to-treat patient population of lenvatinib/pembrolizumab versus sunitinib," said Thomas E. Hutson, DO, PharmD, FACP.
Cabozantinib plus nivolumab/ipilimumab shows promise in renal cell carcinoma with variant histology
Overall, 86% maintained a response for greater than 6 months.
Belzutifan/lenvatinib combo shows promise in renal cell carcinoma
Belzutifan plus lenvatinib elicited promising antitumor activity with a manageable safety profile as a second-line or later treatment for patients with advanced renal cell carcinoma.
Radium-223 yields OS of approximately 18 months in mCRPC
“Our observations in this study show that radium-223 can be integrated into the treatment sequence for patients with (metastatic castration-resistant prostate cancer),” said Daniel Y. Song, MD.
Talazoparib/enzalutamide combo shows manageable safety profile in mCRPC
A total of 398 patients with mCRPC, unselected for homologous recombination repair gene alterations.were included in the safety cohort.
Darolutamide is linked to longer time to treatment discontinuation in nmCRPC
The proportion of patients who discontinued initial ARI treatment was 30.4% for darolutamide compared with 40.8% for enzalutamide and 46.0% for apalutamide.
2 Clarke Drive Cranbury, NJ 08512